256 related articles for article (PubMed ID: 19010312)
61. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
Endo S; Hu D; Matsunaga T; Otsuji Y; El-Kabbani O; Kandeel M; Ikari A; Hara A; Kitade Y; Toyooka N
Bioorg Med Chem; 2014 Oct; 22(19):5220-33. PubMed ID: 25182963
[TBL] [Abstract][Full Text] [Related]
62. Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Jia Y; Domenico J; Swasey C; Wang M; Gelfand EW; Lucas JJ
PLoS One; 2014; 9(5):e97448. PubMed ID: 24848372
[TBL] [Abstract][Full Text] [Related]
63. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Miller VL; Lin HK; Murugan P; Fan M; Penning TM; Brame LS; Yang Q; Fung KM
Int J Clin Exp Pathol; 2012; 5(4):278-89. PubMed ID: 22670171
[TBL] [Abstract][Full Text] [Related]
64. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
65. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
66. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
67. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.
Bauman DR; Rudnick SI; Szewczuk LM; Jin Y; Gopishetty S; Penning TM
Mol Pharmacol; 2005 Jan; 67(1):60-8. PubMed ID: 15475569
[TBL] [Abstract][Full Text] [Related]
68. Two pathways for prostaglandin F2 alpha synthesis by the primate periovulatory follicle.
Dozier BL; Watanabe K; Duffy DM
Reproduction; 2008 Jul; 136(1):53-63. PubMed ID: 18390687
[TBL] [Abstract][Full Text] [Related]
69. Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis.
Nakamura Y; Hornsby PJ; Casson P; Morimoto R; Satoh F; Xing Y; Kennedy MR; Sasano H; Rainey WE
J Clin Endocrinol Metab; 2009 Jun; 94(6):2192-8. PubMed ID: 19336506
[TBL] [Abstract][Full Text] [Related]
70. Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily.
Jin Y; Duan L; Chen M; Penning TM; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):139-44. PubMed ID: 22210085
[TBL] [Abstract][Full Text] [Related]
71. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
72. Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Chang TS; Lin HK; Rogers KA; Brame LS; Yeh MM; Yang Q; Fung KM
Int J Clin Exp Pathol; 2013; 6(11):2419-29. PubMed ID: 24228104
[TBL] [Abstract][Full Text] [Related]
73. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
Azzarello JT; Lin HK; Gherezghiher A; Zakharov V; Yu Z; Kropp BP; Culkin DJ; Penning TM; Fung KM
Int J Clin Exp Pathol; 2009 Nov; 3(2):147-55. PubMed ID: 20126582
[TBL] [Abstract][Full Text] [Related]
74. Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer.
Pippione AC; Kovachka S; Vigato C; Bertarini L; Mannella I; Sainas S; Rolando B; Denasio E; Piercy-Mycock H; Romalho L; Salladini E; Adinolfi S; Zonari D; Peraldo-Neia C; Chiorino G; Passoni A; Mirza OA; Frydenvang K; Pors K; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
Eur J Med Chem; 2024 Mar; 268():116193. PubMed ID: 38364714
[TBL] [Abstract][Full Text] [Related]
75. Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities.
Hendriks CM; Penning TM; Zang T; Wiemuth D; Gründer S; Sanhueza IA; Schoenebeck F; Bolm C
Bioorg Med Chem Lett; 2015 Oct; 25(20):4437-40. PubMed ID: 26372652
[TBL] [Abstract][Full Text] [Related]
76. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
[TBL] [Abstract][Full Text] [Related]
77. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
Gobec S; Brozic P; Rizner TL
Bioorg Med Chem Lett; 2005 Dec; 15(23):5170-5. PubMed ID: 16183274
[TBL] [Abstract][Full Text] [Related]
78. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
79. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
[TBL] [Abstract][Full Text] [Related]
80. Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin.
Lovering AL; Ride JP; Bunce CM; Desmond JC; Cummings SM; White SA
Cancer Res; 2004 Mar; 64(5):1802-10. PubMed ID: 14996743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
